TCM
MYGN icon

Tekla Capital Management’s Myriad Genetics MYGN Stock Holding History

Tekla Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-74,800
Closed -$2.65M – 128
2015
Q1 		$2.65M Buy
+74,800
New +$2.68M 0.1% 102
2014
Q4 		– Sell
-112,200
Closed -$4.33M – 105
2014
Q3 		$4.33M Buy
+112,200
New +$4.19M 0.2% 85

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Tekla Capital Management's MYGN Position: Q1 2020 in Review

Tekla Capital Management sold out of Myriad Genetics (MYGN) in Q1 2020, closing a stake of 18,805 shares — an estimated $512K sold.

Tekla Capital Management first reported a position in MYGN in Q3 2014 and held it in 8 quarters. The position peaked at $4.33M in Q3 2014. 190 funds tracked by Wall St. Rank hold MYGN as of Q1 2020.

  • Tekla Capital Management reported no remaining Myriad Genetics position as of Q1 2020 after selling out during the quarter.
  • Tekla Capital Management sold 18,805 Myriad Genetics shares in Q1 2020, an estimated $512K.
  • Tekla Capital Management first reported a position in Myriad Genetics in Q3 2014 and held it in 8 quarters.
  • Tekla Capital Management's Myriad Genetics position peaked at $4.33M in Q3 2014.
  • 190 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2020.

Based on Tekla Capital Management's 13F filing for Q1 2020, filed 14 May 2020.